Chugai Pharmaceutical stock: Macquarie sets JPY 7,300.00 target for Chugai Pharmaceutical stock

Published on 10/19/2026 at 15:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due on October 27, 2026. Chugai Pharmaceutical stock costs EUR 35.55 on October 19, 2026, down 0.30 percent on Tokyo.

Analyst valuation and trading data

On October 16, 2026, Macquarie maintained Buy and set a JPY 7,300.00 target.
Chugai Pharmaceutical scheduled its fiscal 2026 third-quarter results for October 27, 2026.
Chugai Pharmaceutical stock costs EUR 35.55 at Lang & Schwarz on October 19, 2026 at 3:17 p.m. CEST, down 0.30 percent on the Tokyo Stock Exchange.
The stock traded at a P/E ratio of 22.11 with market capitalization of JPY 10.4 trillion on October 19, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Macquarie maintained its Buy rating on Chugai Pharmaceutical and set a JPY 7,300.00 price target on October 16, 2026, according to Markets Insider. At the Tokyo closing price of JPY 6,334 on October 19, 2026, that target stood 15.25 percent above the stock.

Chugai Pharmaceutical stock was trading at EUR 35.55 at Lang & Schwarz on October 19, 2026 at 3:17 p.m. CEST. The Tokyo listing was down 0.30 percent on the day, from JPY 6,353.00 to JPY 6,334.00.

Results date arrives October 27, 2026

Chugai's next scheduled report is its fiscal 2026 third-quarter result for the January to September period. The company lists the release for October 27, 2026 at 5:00 p.m. JST, followed by a results conference at 6:00 p.m. JST, according to its Chugai Pharmaceutical investor-relations page.

Price position and trading activity

Chugai's Tokyo share price stood at JPY 6,334.00 on October 19, 2026, within a 52-week range of JPY 5,974.00 to JPY 10,700.00. The price was 6.03 percent above the 52-week low and 40.80 percent below the high. Trading volume reached 2,363,000 shares, compared with an average volume of 2,931,200 shares.

Valuation and analyst target

The stock carried a price-to-earnings ratio of 22.11 and a dividend yield of 0.03 percent on October 19, 2026. Market capitalization was JPY 10.4 trillion. Macquarie's JPY 7,300.00 target gives the stock a defined valuation reference, while the upcoming results may provide the next company-specific figure for investors.

Comparison with peers

Chugai Pharmaceutical: minus 0.30 percent, P/E 22.11, market capitalization JPY 10.4 trillion
Takeda Pharmaceutical Company (Tokyo Stock Exchange, JPY): plus 0.34 percent, P/E 55.66, market capitalization JPY 9.9 trillion
Astellas Pharma (Tokyo Stock Exchange, JPY): plus 0.27 percent, P/E 11.94, market capitalization JPY 4.3 trillion

Stock price and the next date

Chugai is listed on the Tokyo Stock Exchange Prime Market under ticker 4519, according to a company overview published by Note. The combination of a JPY 7,300.00 analyst target and the October 27, 2026 reporting date gives the stock two concrete reference points beyond its daily quotation.

Chugai Pharmaceutical stock was trading at EUR 35.55 at Lang & Schwarz on October 19, 2026 at 3:17 p.m. CEST, while its Tokyo listing was down 0.30 percent on the day. The bid was EUR 35.19 and the ask was EUR 35.91. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.